Cresilon, Inc.

BROOKLYN, NY · Medtech · Private

Plant-based hemostatic material that stops traumatic and surgical bleeding without manual pressure

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · cresilon.com

Sector: Medtech
Headquarters: BROOKLYN, NY
Latest Form D: $5M, Apr 2026
Total capital: $134M

Federal grants: $75K; 1 award · 2026; Rank in peer group#6 of 50
Private capital raised: $134M; 8 Form D · last Apr 2026; 6 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 5; 8 pending · first 2017; Rank in peer group#15 of 50

Capital timeline

Latest events

Jul 2026Federal grantDefense · Phase I · Traumagel: A Novel Hemostatic Device For Rapid, Reliable Hemorrhage Control$75K
Apr 2026Private capital raisedForm D · SEC · 8th filing$5M
Dec 2025Private capital raisedForm D · SEC · 7th filing$6.7M
Sep 2025Private capital raisedForm D · SEC · 6th filing$17.2M
Jan 2025Private capital raisedForm D · SEC · 5th filing$25M
Oct 2024Private capital raisedForm D · SEC · 4th filing$17.2M
Oct 2022Private capital raisedForm D · SEC · 3rd filing$25M
Feb 2021Private capital raisedForm D · SEC · 2nd filing$24.5M
Jan 2018Private capital raisedForm D · SEC · 1st filing$13.3M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 50 peers

Line = median

Medtech · Material

Federal grants#6 · top 12%
Granted patents#15 · top 30%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Joseph LandolinaResearcherExecutive Officer, DirectorLinked by 4 patents
Isaac MillerExecutive Officer, DirectorNamed in SEC Form D filings
Scott LevineExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 5 granted of 13

May 22, 2025PendingHighly Efficacious Hemostatic Adhesive Polymer ScaffolUSPTOApplication 18747686
Jun 25, 2024GrantedHighly Efficacious Hemostatic Adhesive Polymer ScaffoldUSPTOUS 12,016,968
Jun 1, 2023PendingDelivery Device For Hemostatic CompositionsUSPTOApplication 17881183

Show all 13 patent records

Highly Efficacious Hemostatic Adhesive Polymer ScaffolMay 22, 2025 · Application 18747686Pending
Highly Efficacious Hemostatic Adhesive Polymer ScaffoldJun 25, 2024 · US 12,016,968Granted
Delivery Device For Hemostatic CompositionsJun 1, 2023 · Application 17881183Pending
In-situ Cross-linkable Polymeric Compositions And Methods ThereofJul 12, 2022 · US 11,383,005Granted
Delivery Device For Hemostatic CompositionsFeb 2, 2021 · US D,909,570Granted
In-situ Cross-linkable Polymeric Compositions And Methods ThereofDec 1, 2020 · US 10,850,003Granted
Delivery Device For Hemostatic CompositionsSep 19, 2019 · Application 15920362Pending
Highly Efficacious Hemostatic Adhesive Polymer ScaffoldJul 5, 2018 · Application 15739095Pending
In-situ Cross-linkable Polymeric Compositions And Methods ThereofJun 27, 2017 · US 9,687,584Granted
Hemostatic Compositions With Antifibrinolytic AgentsApplication PCTUS2017068033Pending
Delivery Device For Hemostatic CompositionsApplication PCTUS2019022043Pending
Hemostatic Compositions With Clotting AgentsApplication 62437631Pending
Highly Efficacious Hemostatic Adhesive Polymer ScaffoldApplication PCTUS2015036894Pending

EXO DYNAMICS LLCSimilar federal contract value in Medtech · null in contracts
LinguaFlex, Inc.Similar federal contract value in Medtech · null in contracts
MIRA MEDICAL, LLCSimilar federal contract value in Medtech · null in contracts
Biomarker CorporationSimilar federal contract value in Medtech · null in contracts
DILISYM SERVICES, INC.Similar federal contract value in Medtech · null in contracts
OSTEODX INCSimilar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.